Wall Street Jouranl -- Eli Lilly & Co. Chief Executive John Lechleiter is facing a drug-maker’s nightmare. Starting as soon as this year, he’ll lose U.S. patent protection for eight drugs in as many years, clearing the way for generic competition to erode Lilly’s sales. The drugs currently generate about three-fourths of Lilly’s annual revenue.
